...
首页> 外文期刊>Biological research: BR >Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation
【24h】

Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation

机译:敲低SETDB1通过miR-381-3p相关调控抑制乳腺癌进展

获取原文
   

获取外文期刊封面封底 >>

       

摘要

SET domain bifurcated 1 (SETDB1) has been widely considered as an oncogene playing a critical role in many human cancers, including breast cancer. Nevertheless, the molecular mechanism by which SETDB1 regulates breast cancer tumorigenesis is still unknown. qRT-PCR assay or western blot analysis was performed to assess the expression level of SETDB1 mRNA or protein, respectively. siSETDB1, pCMV6-XL5-SETDB1, miR-381-3p mimic, or miR-381-3p inhibitor was transfected into cells to regulate the expression of SETDB1 or miR-381-3p. MiRNA directly interacted with SETDB1 was verified by luciferase reporter assay and RNA immunoprecipitation. CCK-8 assay, colony formation assay, flow cytometric analysis, and transwell assay were used to detect the abilities of cell proliferation, cell cycle progression and migration, respectively. Animal model of xenograft tumor was used to observe the regulatory effect of SETDB1 on tumor growth in vivo. We verified that SETDB1 mRNA level was upregulated in breast cancer tissues and cell lines, and SETDB1 depletion led to a suppression of cell proliferation, cell cycle progression and migration in vitro, as well as tumor growth in vivo. SETDB1 was verified to be a target of miR-381-3p. Moreover, miR-381-3p overexpression suppressed cell proliferation, cell cycle progression and migration, whereas SETDB1 abated miR-381-3p-mediated regulatory function on breast cancer cells. This study revealed that SETDB1 knockdown might suppress breast cancer progression at least partly by miR-381-3p-related regulation, providing a novel prospect in breast cancer therapy.
机译:SET域分叉1(SETDB1)已被广泛认为是致癌基因,在许多人类癌症(包括乳腺癌)中起着至关重要的作用。然而,SETDB1调节乳腺癌肿瘤发生的分子机制仍然未知。进行qRT-PCR测定或蛋白质印迹分析以分别评估SETDB1 mRNA或蛋白质的表达水平。将siSETDB1,pCMV6-XL5-SETDB1,miR-381-3p模仿物或miR-381-3p抑制剂转染到细胞中以调节SETDB1或miR-381-3p的表达。直接与SETDB1相互作用的MiRNA已通过荧光素酶报告基因检测和RNA免疫沉淀法得到验证。使用CCK-8测定,集落形成测定,流式细胞术分析和transwell测定来分别检测细胞增殖,细胞周期进程和迁移的能力。使用异种移植肿瘤的动物模型观察SETDB1对体内肿瘤生长的调节作用。我们证实,SETDB1 mRNA水平在乳腺癌组织和细胞系中上调,并且SETDB1的耗竭导致体外抑制细胞增殖,细胞周期进程和迁移以及体内肿瘤生长。已确认SETDB1是miR-381-3p的靶标。此外,miR-381-3p的过表达抑制细胞增殖,细胞周期进程和迁移,而SETDB1减弱了miR-381-3p介导的乳腺癌细胞调节功能。这项研究表明,SETDB1基因敲低可能至少部分地通过miR-381-3p相关调节抑制乳腺癌的进展,为乳腺癌治疗提供了新的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号